Congratulations to Sciad Communications’ clients – 2018 in Review
Congratulations to all our clients on another successful year. Here are some of our news highlights – Bring on 2019!
Several of our clients have been recognised this year for their progress and contributions to their respective industries.
- International Trade and Innovation – Queen’s Awards for Enterprise
- 27th – Deloitte UK Technology Fast 50
As well as gaining award recognition, this year has seen a number of our clients secure new funding to continue their research and fund further growth.
- £118,000 – Innovate UK – Develop a new biophysical screening method for G-protein coupled receptors (GPCRs)
- £235,000 – Innovate UK – Evaluate inducible promoter platform in collaboration with Lonza
- £1.9M – Scottish Enterprise – Expand Synpromics’ R&D programmes in gene regulation for cell and gene medicines
- Medicines Manufacturing Grant – Innovate UK – Extend its pilot scale manufacture of patches formulated with its unique TEPI Patch® technology to GMP manufacture for clinical trials
- Innovate UK – Expand network model of the outer wall of Gram-negative bacteria
- $10million – Saudi, Swedish and Korean Investors– Clinical development of revolutionary thermostable vaccines
- $55million – Series B Funding Round – Advance RSV clinical studies into Phase IIa paediatric and adult trials
Three clients have launched new parts of their businesses including a huge scientific/medical research award and new technology to aid scientific reproducibility and collaboration.
British Heart Foundation
- Big Beat Challenge – £30 million award to identify and solve any of the biggest problems in heart and circulatory disease
- Open Access – provides free use of the Scientific Development Environment for next-generation design and publishing of experiments to academics and non-profits
- Peer Science Coin – A new blockchain-based payment token for scientists and academic institutions collaborating on peerwith.com
Working with a range of life science and technology firms, we see a number of exciting projects and cutting edge research. Two of our clients reached successful clinical trial mile stones this year.
- Positive Phase I results – Completion of first clinical safety studies of the TEPI Patch
- Positive phase II results – RV521, an oral RSV fusion inhibitor significantly reduced viral load, reduced total mucus weight and reduced clinical symptoms, compared to placebo
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.